Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study

Abstract

Background We investigate the association between mean HbA1c, HbA1c variability, and all-cause mortality and diabetes-related macrovascular complications in patients with diabetes. Methods We performed a retrospective cohort study using patients present in the Singapore Health Services diabetes registry (SDR) during 2013 to 2014. We assessed mean HbA1c using three models: a baseline mean HbA1c for 2013–14, the mean across the whole follow-up period, and a time-varying yearly updated mean. We assessed HbA1c variability at baseline using the patient’s HbA1c variability score (HVS) for 2013–14. The association between mean HbA1c, HVS, and 6 outcomes were assessed using Cox proportional hazard models. Results We included 43,837–53,934 individuals in the analysis; 99.3% had type 2 diabetes mellitus. The data showed a J-shaped distribution in adjusted hazard ratios (HRs) for all-cause mortality, ischemic heart disease, acute myocardial infarction, peripheral arterial disease, and ischemic stroke, with an increased risk of developing these outcomes at HbA1c <6% (42 mmol/mol) and ≥8% (64 mmol/mol). With the addition of HVS, the J-shaped distribution was maintained for the above outcomes, but HRs were greater at HbA1c <6.0% (42 mmol/mol) and reduced at HbA1c ≥8.0% (64 mmol/mol) when compared to models without HVS. The risk for all outcomes increased substantially with increasing glycaemic variability. Conclusion Both low (<6.0% [42 mmol/mol]) and high (≥8.0% [64 mmol/mol]) levels of glycaemic control are associated with increased all-cause mortality and diabetes-related macrovascular complications. Glycaemic variability is independently associated with increased risk for these outcomes. Therefore, patients with stable glycaemic level of 6–8% (42–64mmol/mol) are at lowest risk of all-cause mortality and diabetes-related macrovascular complications.

Potential Impact of Metabolic Syndrome Control on Cardiovascular Risk in Elderly Patients with Diabetes: A Cross-Sectional Study

“…HbA1c levels, reflecting the glycemic control, are associated with the reduction of non-fatal CV events, such as stroke, and microvascular and macrovascular complications [38][39][40]. For this reason, achieving good glycemic control is currently a recommended goal in the individualized approach to all individuals with diabetes [41].…”

Assessment of Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus on Insulin Therapy

“…Согласно исследованиям ARIC, UKPDS и ADVANCE было доказано, что увеличение гликированного гемоглобина на 1% (начальный уровень HbA1c от 6,5%) почти в 2 раза повышало риск микрососудистых осложнений, а при исходном уровне HbA1c от 7% уже возрастал риск и макрососудистых заболеваний на 38%. В то же время снижение этого показателя на 1% приводило к снижению сердечно-сосудистой и общей смертности на 25% и 22% соответственно [9]. В связи с чем был проведен анализ показателей НbА1с в зависимости от группы риска, результаты которого представлены в табл.…”

A moderately higher time-in-range threshold improves the prognosis of type 2 diabetes patients complicated with COVID-19

“…These associations between diabetes and worse outcomes in COVID-19 patients were incontrovertible, as blood glucose fluctuation was not conducive to the improvement of disease, and inflammation caused by hyperglycemia led to increased mortality ( 7 , 8 ). However, excessively tight glycemic control may increase the risk of hypoglycemia, which also increased mortality ( 9 ).The impact of COVID-19 on the patients and the use of glucocorticoids and nutritional support during the treatment increased blood glucose fluctuations, which had adverse effects on the prognosis ( 10 ).…”